Spolia Therapeutics was founded in 2023 to advance treatments for neurodegeneration by targeting metabolic dysregulation in disease. We’re driven by a clear goal: to bring science-backed, precision-targeted solutions to patients and families who urgently need them.

VISIT WEBSITE